IL-21 Influences the Frequency, Phenotype, and Affinity of the Antigen-specific CD8 T Cell Response
Overview
Authors
Affiliations
IL-21, a newly described cytokine belonging to the IL-2 gamma-chain receptor cytokine family (that includes IL-2, IL-7, and IL-15), has been described as an important regulator of the cellular immune response. In this study, the role of IL-21 in the generation of a human Ag-specific CD8+ T cell response is characterized by tracking a rare, but measurable population of self-Ag-specific T cells in vitro. Autologous dendritic cells pulsed with the melanoma antigen recognized T cells 1 self-peptide were used to stimulate CD8+ T cells from HLA-A2+ healthy donors and melanoma patients. We demonstrate that exposure to IL-21 increased the total number of MART-1-specific CD8+ T cells that could be elicited by >20-fold and, at the clonal level, enriched for a population of high-affinity CD8+ T cells with a peptide dose requirement more than 1 log(10)-fold less than their untreated counterparts. Phenotypic analysis of T cells from IL-21-treated cultures revealed a unique population of CD45RO+ CD28(high) CD8+ T cells, a phenotype that was stable for at least 4 wk after IL-21 exposure. These CD28(high) CD8+ T cells produced IL-2 upon Ag stimulation and represent potential helper-independent CTLs. Our studies demonstrate a significant role for IL-21 in the primary Ag-specific human CTL response and support the use of IL-21 in the ex vivo generation of potent Ag-specific CTLs for adoptive therapy or as an adjuvant cytokine during in vivo immunization against tumor Ags.
Balkhi S, Bilato G, De Lerma Barbaro A, Orecchia P, Poggi A, Mortara L Vaccines (Basel). 2025; 13(1).
PMID: 39852848 PMC: 11768832. DOI: 10.3390/vaccines13010069.
Yee C, Saxena K, Ryu E, Hung S, Singh S, Zhang Q Res Sq. 2024; .
PMID: 39711535 PMC: 11661303. DOI: 10.21203/rs.3.rs-5307127/v1.
Kureshi C, Dougan S Cancer Cell. 2024; 43(1):15-35.
PMID: 39672170 PMC: 11841838. DOI: 10.1016/j.ccell.2024.11.011.
Advances and prospects in tumor infiltrating lymphocyte therapy.
Qiu X, Li S, Fan T, Zhang Y, Wang B, Zhang B Discov Oncol. 2024; 15(1):630.
PMID: 39514075 PMC: 11549075. DOI: 10.1007/s12672-024-01410-5.
Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy.
Lecoultre M, Walker P, El Helali A Clin Exp Med. 2024; 24(1):202.
PMID: 39196415 PMC: 11358230. DOI: 10.1007/s10238-024-01443-8.